Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 1/20 | 0.48 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.48 |
| ▸ | ESR1 | P03372 | 2/20 | 0.39 |
| ▸ | ESR2 | Q92731 | 2/20 | 0.39 |
| ▸ | DRD1 | P21728 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3011683 | 0.78 | CYP3A4 (0.50) | CYP3A4TDP1ESR1ESR2DRD1 | |
| SCHEMBL2988710 | 0.78 | — | — | |
| SCHEMBL28587099 | 0.76 | CYP3A4 (0.48) | CYP3A4TDP1ESR1ESR2DRD1 | |
| SCHEMBL17157063 | 0.76 | CYP3A4 (0.48) | CYP3A4TDP1ESR1ESR2DRD1 | |
| SCHEMBL7539350 | 0.76 | CYP3A4 (0.48) | CYP3A4TDP1ESR1ESR2DRD1 | |
| SCHEMBL1929940 | 0.76 | CYP3A4 (0.48) | CYP3A4TDP1ESR1ESR2DRD1 | |
| SCHEMBL10591398 | 0.76 | CYP3A4 (0.48) | CYP3A4TDP1ESR1ESR2DRD1 | |
| SCHEMBL18641305 | 0.76 | CYP3A4 (0.48) | CYP3A4TDP1ESR1ESR2DRD1 | |
| SCHEMBL7644177 | 0.75 | — | — | |
| SCHEMBL5732165 | 0.75 | CYP3A4 (0.46) | CYP3A4TDP1ESR1ESR2DRD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7365011-B2 | Catalytic nucleation monolayer for metal seed layers | INTEL CORPORATION (US) | 2008-04-29 | — | — | US | claimed |
| US-20070105375-A1 | Catalytic nucleation monolayer for metal seed layers | INTEL CORPORATION | 2007-05-10 | — | — | US | claimed |
| US-7365011-B2 | Catalytic nucleation monolayer for metal seed layers | INTEL CORPORATION (US) | 2008-04-29 | — | — | US | disclosed |
| US-20070105375-A1 | Catalytic nucleation monolayer for metal seed layers | INTEL CORPORATION | 2007-05-10 | — | — | US | disclosed |
| US-20030065117-A1 | Modified silicone compound, process of producing the same, and cured object obtained therefrom | NATIONAL INSTITUTE OF ADVANCED INDUSTRIAL SCIENCE AND TECHNOLOGY (JP) | 2003-04-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030065117-A1 | Modified silicone compound, process of producing the same, and cured object obtained therefrom | ORMDL3, SGMS1, HEATR1 | CYP3A4 3550/4885TDP1 4547/4885ESR1 758/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.